Kristian Ängeby

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Journal article: HPB. 2024;26:s454
Differences in cholecystectomy outcomes and operating time: a comparison of surgeons experience and formal competence
Fathalla B; Sandblom G; Berglund E; Ängeby K
Journal article: HPB. 2024;26:s455-s456
Preoperative predictors of postoperative infectious complications in acute cholecystitis: a blinded case-control study
Fathalla B; Islam MR; Sandblom G; Berglund E; Ängeby K
Article: LAKARTIDNINGEN. 2022;119:22066
[Jaundice in the adult patient].
Kourie M; Ängeby K; Sjöström M; Fagerström N
Article: BMJ OPEN. 2022;12(9):e060679
Stockholm score of lesion detection on computed tomography following mild traumatic brain injury (SELECT-TBI): study protocol for a multicentre, retrospective, observational cohort study
Fletcher-Sandersjoo A; Tatter C; Yang L; Ponten E; Boman M; Lassaren P; Forsberg S; Gronlund I; Tidehag V; Rubenson-Wahlin R; Strommer L; Westberg K; Angeby K; Djarv T; Lundblad O; Bartek JJ; Thelin EP
Article: TUBERCULOSIS. 2020;123:101959
CD4⁺ T cell proliferative responses to PPD and CFP-10 associate with recent M. tuberculosis infection
Borgstrom EW; Froberg G; Correia-Neves M; Atterfelt FB; Bellbrant J; Szulkin R; Chryssanthou E; Angeby K; Tecleab T; Ruhwald M; Andersen P; Kallenius G; Bruchfeld J
Article: GENOME MEDICINE. 2020;12(1):27
Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex
Merker M; Kohl TA; Barilar I; Andres S; Fowler PW; Chryssanthou E; Angeby K; Jureen P; Moradigaravand D; Parkhill J; Peacock SJ; Schon T; Maurer FP; Walker T; Koser C; Niemann S
Article: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2016;71(2):333-338
Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB
Niward K; Angeby K; Chryssanthou E; Paues J; Bruchfeld J; Jureen P; Giske CG; Kahlmeter G; Schon T
Article: JOURNAL OF LARYNGOLOGY AND OTOLOGY. 2015;129(7):644-655
Otomastoiditis caused by non-tuberculous mycobacteria: report of 16 cases, 3 with infection intracranially
Lundman L; Edvardsson H; Angeby K
Article: INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY. 2015;4 Suppl 1:80-81
Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
Article: CLINICAL MICROBIOLOGY AND INFECTION (CMI). 2015;21(2):148.e5-148.e7
Little difference between minimum inhibitory concentrations of Mycobacterium tuberculosis wild-type organisms determined with BACTEC MGIT 960 and Middlebrook 7H10
Sturegard E; Angeby KA; Werngren J; Jureen P; Kronvall G; Giske CG; Kahlmeter G; Schon T
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2015;59(6):3630-3632
Meropenem-Clavulanic Acid Has High In Vitro Activity against Multidrug-Resistant Mycobacterium tuberculosis
Forsman LD; Giske CG; Bruchfeld J; Schon T; Jureen P; Angeby K
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58(12):7557-7559
Intra- and Extracellular Activities of Trimethoprim-Sulfamethoxazole against Susceptible and Multidrug-Resistant Mycobacterium tuberculosis
Forsman LD; Scohn T; Simonsson USH; Bruchfeld J; Larsson M; Jureen P; Sturegard E; Giske CG; Angeby K
Article: JOURNAL OF MICROBIOLOGICAL METHODS. 2014;106:146-150
A luciferase-based assay for rapid assessment of drug activity against Mycobacterium tuberculosis including monitoring of macrophage viability
Larsson MC; Lerm M; Angeby K; Nordvall M; Jureen P; Schon T
Article: BMC RESEARCH NOTES. 2014;7:512
A 24-well plate assay for simultaneous testing of first and second line drugs against Mycobacterium tuberculosis in a high endemic setting.
Wedajo W; Schön T; Bedru A; Kiros T; Hailu E; Mebrahtu T; Yamuah L; Ängeby K; Werngren J; Onyebujoh P; Dagne K; Aseffa A
Article: EUROPEAN RESPIRATORY JOURNAL. 2013;42(6):1604-1613
The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples An NTM-NET collaborative study
Hoefsloot W; Van Ingen J; Andrejak C; Angeby K; Bauriaud R; Bemer P; Beylis N; Boeree MJ; Cacho J; Chihota V; Chimara E; Churchyard G; Cias R; Daza R; Daley CL; Dekhuijzen PNR; Domingo D; Drobniewski F; Esteban J; Fauvilte-Dufaux M; Folkvardsen DB; Gibbons N; Gomez-Mampaso E; Gonzalez R; Hoffmann H; Hsueh P-R; Indra A; Jagielski T; Jamieson F; Jankovic M; Jong E; Keane J; Koh W-J; Lange B; Leao S; Macedo R; Mannsaker L; Marras TK; Maugein J; Milburn HJ; Mlinko T; Morcillo N; Morimoto K; Papaventsis D; Palenque E; Paez-Peria M; Piersimoni C; Polanova M; Rastogi N; Richter E; Ruiz-Serrano MJ; Silva A; da Silva MP; Simsek H; van Soolingen D; Szabo N; Thomson R; Fernandez TT; Tortoli E; Totten SE; Tyrrell G; Vasankari T; Villar M; Walkiewicz R; Winthrop KL; Wagner D
Article: INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE. 2013;17(11):1486-1490
Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experience
Hoffner S; Angeby K; Sturegard E; Jonsson B; Johansson A; Sellin M; Werngren J
Article: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2013;68(9):2074-2077
Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact?
Schon T; Jureen P; Chryssanthou E; Giske CG; Kahlmeter G; Hoffner S; Angeby K
Article: INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY. 2012;1(4):177-179
Tentative susceptibility testing breakpoint for the neuroleptic drug thioridazine, a treatment option for multi- and extensively drug resistant tuberculosis.
Ängeby K; Juréen P; Chryssanthou E; Schön T
Article: BULLETIN OF THE WORLD HEALTH ORGANIZATION. 2012;90(9):693-698
Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis
Angeby K; Jureen P; Kahlmeter G; Hoffner SE; Schon T
Article: APMIS. 2012;120(5):405-409
The GenoType® MTBDRplus assay for detection of drug resistance in Mycobacterium tuberculosis in Sweden
Chryssanthou E; Angeby K
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2012;56(3):1253-1257
Reevaluation of the Critical Concentration for Drug Susceptibility Testing of Mycobacterium tuberculosis against Pyrazinamide Using Wild-Type MIC Distributions and pncA Gene Sequencing
Werngren J; Sturegard E; Jureen P; Angeby K; Hoffner S; Schon T
Article: PLOS ONE. 2012;7(6):e39891
Resistance to First-Line Anti-TB Drugs Is Associated with Reduced Nitric Oxide Susceptibility in Mycobacterium tuberculosis
Idh J; Mekonnen M; Abate E; Wedajo W; Werngren J; Angeby K; Lerm M; Elias D; Sundqvist T; Aseffa A; Stendahl O; Schon T
Article: INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE. 2011;15(4):502-509
Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis
Schon T; Jureen P; Chryssanthou E; Giske CG; Sturegard E; Kahlmeter G; Hoffner S; Angeby KA
Article: PLOS ONE. 2010;5(11):e13839
Antioxidants Protect Keratinocytes against M-ulcerans Mycolactone Cytotoxicity
Gronberg A; Zettergren L; Bergh K; Stahle M; Heilborn J; Angeby K; Small PL; Akuffo H; Britton S
Article: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2010;65(5):946-952
Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data
Angeby KA; Jureen P; Giske CG; Chryssanthou E; Sturegard E; Nordvall M; Johansson AG; Werngren J; Kahlmeter G; Hoffner SE; Schon T
Article: JOURNAL OF CLINICAL MICROBIOLOGY. 2010;48(5):1853-1858
Wild-Type MIC Distributions for Aminoglycoside and Cyclic Polypeptide Antibiotics Used for Treatment of Mycobacterium tuberculosis Infections
Jureen P; Angeby K; Sturegard E; Chryssanthou E; Giske CG; Werngren J; Nordvall M; Johansson A; Kahlmeter G; Hoffner S; Schon T
Article: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2009;64(4):786-793
Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis
Schon T; Jureen P; Giske CG; Chryssanthou E; Sturegard E; Werngren J; Kahlmeter G; Hoffner SE; Angeby KA
Article: JOURNAL OF CLINICAL MICROBIOLOGY. 2005;43(7):3159-3161
Drug susceptibility testing of Mycobacterium tuberculosis by a nitrate reductase assay applied directly on microscopy-positive sputum samples.
Musa HR; Ambroggi M; Souto A; Angeby KAK
Journal article: JOURNAL OF CLINICAL MICROBIOLOGY. 2002;40(10):3881-3882
Nitrate reductase assay for drug susceptibility testing of Mycobacterium tuberculosis.
Panaiotov S; Kantardjiev T
Article: JOURNAL OF CLINICAL MICROBIOLOGY. 2002;40(2):553-555
Rapid and inexpensive drug susceptibility testing of Mycobacterium tuberculosis with a nitrate reductase assay.
Angeby KAK; Klintz L; Hoffner SE
Article: INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE. 2000;4(7):684-687
Improved sputum microscopy for a more sensitive diagnosis of pulmonary tuberculosis.
Angeby KA; Alvarado-Gálvez C; Pineda-García L; Hoffner SE
Visa fler

Alla övriga publikationer

Preprint: RESEARCH SQUARE. 2023
Automatic identification of community-onset sepsis among patients attending an emergency department – a validation study
Duré C; Jonmarker S; Bohm K; Nordqvist H; Joelsson-Alm E; Rimling L; Franko MA; Cronhjort M; Ängeby K
Letter: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2011;55(9):4492-4493
Wild-Type MIC Distributions Must Be Considered To Set Clinically Meaningful Susceptibility Testing Breakpoints for All Bacterial Pathogens, Including Mycobacterium tuberculosis
Angeby K; Giske CG; Jureen P; Schon T
Review: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2008;62(1):56-64
The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis:: a systematic review and meta-analysis
Martin A; Panaiotov S; Portaels F; Hoffner S; Palomino JC; Angeby K
Letter: INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE. 2005;9(6):700-701
Will the bleach method keep its promise in sputum smear microscopy? : Reply
Ängeby K; Hoffner SE; Diwan VK
Review: INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE. 2004;8(7):806-815
Should the 'bleach microscopy method' be recommended for improved case detection of tuberculosis? Literature review and key person analysis.
Angeby KAK; Hoffner SE; Diwan VK
Thesis / dissertation: 2004
Tuberculosis : diagnosis and drug susceptibility testing where resources are scarce
Ängeby, Kristian
Published conference paper: CLINICAL MICROBIOLOGY AND INFECTION (CMI). 2003;9(11):1148-1152
Evaluation of the BacT/ALERT 3D system for recovery and drug susceptibility testing of Mycobacterium tuberculosis.
Angeby KAK; Werngren J; Toro JC; Hedström G; Petrini B; Hoffner SE

Anställningar

Lektor/Specialistläkare, Klinisk forskning och utbildning, Södersjukhuset, Karolinska Institutet, 2021-

Examina och utbildning

Docent, Akutsjukvård, Karolinska Institutet, 2021
MEDICINE DOKTORSEXAMEN, Institutionen för global folkhälsa, Karolinska Institutet, 2004
Läkarexamen, Karolinska Institutet, 1997

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI